AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21383284 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid chemotherapy
Number of subjects: 1913
Study 21383284 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 1913
Study 19263118 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional mode ultrasonically activated device (TM)
Number of subjects: 151
Study 19263118 — intervention group
Group type: COMPARATOR
Intervention: Linear mode ultrasonically activated device (LM)
Number of subjects: 151
Study 17255220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin suppository (DHA)
Number of subjects: 60
Study 17255220 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular artemether (ART)
Number of subjects: 60
Study 17255220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DHA and ART
Number of subjects: 60
Study 15472673 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of aqueous sodium phosphate (45 mL each)
Number of subjects: 0
Study 15472673 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of aqueous sodium phosphate
Number of subjects: 0
Study 15472673 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of aqueous sodium phosphate
Number of subjects: 0
Study 11486720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 164
Study 11486720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 164
Study 11486720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 9551878 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 334
Study 9551878 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 334
Study 9551878 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 334
Study 9551878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 8038733 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a live harmless snake
Number of subjects: 224
Study 2647472 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 32
Study 30012268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (protein-energy nutritional supplementation) from conception to age 2 years
Number of subjects: 1661
Study 28965562 — intervention group
Group type: EXPERIMENTAL
Intervention: 150g cod
Number of subjects: 38
Study 28965562 — intervention group
Group type: EXPERIMENTAL
Intervention: 150g salmon
Number of subjects: 38
Study 28965562 — intervention group
Group type: EXPERIMENTAL
Intervention: 150g blue mussels
Number of subjects: 38
Study 28965562 — intervention group
Group type: COMPARATOR
Intervention: potato (control)
Number of subjects: 38
Study 26485846 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-prostatic local infiltration anesthesia (PLIA) alone (G1)
Number of subjects: 163
Study 26485846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical anal lignocaine ointment and local infiltration anesthesia (G2)
Number of subjects: 163
Study 23211715 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal supportive care + whole brain radiotherapy (WBRT) (20 Gy in five fractions)
Number of subjects: 151
Study 23211715 — intervention group
Group type: COMPARATOR
Intervention: Optimal supportive care (OSC)
Number of subjects: 151
Study 21986329 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon followed by bare metal stent (DCB first)
Number of subjects: 26
Study 21986329 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent followed by paclitaxel-coated balloon (BMS first)
Number of subjects: 26
Study 21986329 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent first
Number of subjects: 26
Study 21986329 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon first
Number of subjects: 26
Study 21986329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study 18467648 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted locomotor training (LT) for 12 sessions of 30 minutes each
Number of subjects: 48
Study 18467648 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted locomotor training (LT) for 12 sessions of 30 minutes each
Number of subjects: 48
Study 18467648 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted LT
Number of subjects: 48
Study 18467648 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted LT
Number of subjects: 48
Study 17139644 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage plus administration of corticosteroids (ALC)
Number of subjects: 78
Study 17139644 — intervention group
Group type: COMPARATOR
Intervention: Joint aspiration plus administration of corticosteroids (JAC)
Number of subjects: 78
Study 17139644 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lavage plus administration of placebo (ALP)
Number of subjects: 78
Study 17139644 — intervention group
Group type: EXPERIMENTAL
Intervention: High synovial extent of fibrosis after ALC
Number of subjects: 78
Study 12699175 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized ablation
Number of subjects: 20
Study 12699175 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 20
Study 10750366 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (10 mg intravenous drip infusion)
Number of subjects: 14
Study 8997865 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin impregnated sisal curtains
Number of subjects: 523
Study 8997865 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 523
Study 1630802 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV antibody positive patients in chronic haemodialysis
Number of subjects: 155
Study 1630802 — intervention group
Group type: COMPARATOR
Intervention: Polytransfused group
Number of subjects: 155
Study 1630802 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBV and/or HCV infection
Number of subjects: 155
Study 1630802 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for HBV and HCV markers
Number of subjects: 155
Study 6203818 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 50
Study 30573517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (three 8-day periods)
Number of subjects: 24
Study 28960146 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 324
Study 28960146 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic beverage cues
Number of subjects: 324
Study 27000327 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 183
Study 27000327 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 183
Study 27000327 — intervention group
Group type: COMPARATOR
Intervention: Non-canagliflozin (control)
Number of subjects: 183
Study 23473519 — intervention group
Group type: EXPERIMENTAL
Intervention: Air insufflation via a subglottic catheter
Number of subjects: 14
Study 23473519 — intervention group
Group type: COMPARATOR
Intervention: No air insufflation
Number of subjects: 14
Study 22789789 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Number of subjects: 123
Study 22789789 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 123
Study 20007979 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 0
Study 20007979 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 0
Study 17644412 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive screening tests for post-MI patients
Number of subjects: 0
Study 17644412 — intervention group
Group type: EXPERIMENTAL
Intervention: More conservative ICD programming
Number of subjects: 0
Study 17644412 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 0
Study 17644412 — intervention group
Group type: COMPARATOR
Intervention: Dual chamber minimal ventricular pacing
Number of subjects: 0
Study 17644412 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of KW-3902 (selective A1 adenosine receptor antagonist)
Number of subjects: 0
Study 17644412 — intervention group
Group type: COMPARATOR
Intervention: Canrenone
Number of subjects: 0
Study 16326292 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion plus 10 microg/kg of intrathecal morphine (ITM group, n = 23)
Number of subjects: 46
Study 16326292 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion alone (control group, n = 23)
Number of subjects: 46
Study 12003472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power groups
Number of subjects: 0
Study 12003472 — intervention group
Group type: COMPARATOR
Intervention: Low-power groups
Number of subjects: 0
Study 9817281 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose m-BACOD plus GM-CSF
Number of subjects: 192
Study 7807297 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with consecutive esotropia (postoperative)
Number of subjects: 21
Study 7807297 — intervention group
Group type: COMPARATOR
Intervention: Control patients (maintained fusion)
Number of subjects: 21
Study 2571009 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on fatty fish intake
Number of subjects: 2033
Study 2571009 — intervention group
Group type: COMPARATOR
Intervention: Advice on fat intake
Number of subjects: 2033
Study 2571009 — intervention group
Group type: COMPARATOR
Intervention: Advice on fibre intake
Number of subjects: 2033
Study 2571009 — intervention group
Group type: COMPARATOR
Intervention: Dietary regimens overall
Number of subjects: 2033
Study 819200 — intervention group
Group type: COMPARATOR
Intervention: Treatment in air with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Number of subjects: 27
Study 819200 — intervention group
Group type: COMPARATOR
Intervention: Treatment in hyperbaric oxygen (3 atm) with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Number of subjects: 27
Study 819200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Radiation Effect (CRE) analysis of treatment regimes.
Number of subjects: 27
Study 819200 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE level of 1910 reu.
Number of subjects: 27
Study 7407482 — intervention group
Group type: EXPERIMENTAL
Intervention: D-propranolol
Number of subjects: 12
Study 7407482 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study 28715932 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce physical disability
Number of subjects: 147
Study 30123250 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Treatment (AOT)
Number of subjects: 18
Study 30123250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 26377235 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAPe curriculum (intervention group, n=500)
Number of subjects: 998
Study 26377235 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=498)
Number of subjects: 998
Study 24983542 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily
Number of subjects: 0
Study 24983542 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 0
Study 24983542 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0
Study 24983542 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study 22863021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Syllable Transition Treatment
Number of subjects: 20
Study 22863021 — intervention group
Group type: COMPARATOR
Intervention: Nuffield Dyspraxia Programme - Third edition
Number of subjects: 20
Study 19602554 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 131
Study 19602554 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone + Testosterone (GH+T)
Number of subjects: 131
Study 19602554 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T)
Number of subjects: 131
Study 19602554 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 131
Study 17617776 — intervention group
Group type: EXPERIMENTAL
Intervention: Long distance corridor walk (LDCW) time
Number of subjects: 492
Study 15117375 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/clindamycin topical gel (5% benzoyl peroxide and 1% clindamycin)
Number of subjects: 53
Study 15117375 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 53
Study 15117375 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/clindamycin topical gel
Number of subjects: 53
Study 12478408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g t.i.d.)
Number of subjects: 38
Study 12478408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (2 g q.i.d.)
Number of subjects: 38
Study 12478408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 38
Study 9699819 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris hip score
Number of subjects: 100
Study 9699819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile
Number of subjects: 100
Study 8012963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at 3.9 mg/kg and Ciprofloxacin (Cipro) 500 mg p.o. every 12 h on days 1-5 and 10-20.
Number of subjects: 18
Study 8012963 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients receiving IL-2/LAK without PTX/Cipro.
Number of subjects: 18
Study 2595345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg daily
Number of subjects: 10
Study 2595345 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg daily
Number of subjects: 10
Study 785689 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of urokinase
Number of subjects: 327
Study 785689 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of urokinase
Number of subjects: 327
Study 785689 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of streptokinase
Number of subjects: 327
Study 785689 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 327
Study 31270506 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type S. Typhi
Number of subjects: 40
Study 31270506 — intervention group
Group type: COMPARATOR
Intervention: Typhoid toxin deletion mutant (TN) S. Typhi
Number of subjects: 40
Study 28028737 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month sustained-release triptorelin
Number of subjects: 920
Study 28028737 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month sustained-release triptorelin
Number of subjects: 920
Study 28028737 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month sustained-release triptorelin
Number of subjects: 920
Study 28028737 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month sustained-release triptorelin
Number of subjects: 920
Study 28028737 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month sustained-release triptorelin
Number of subjects: 920
Study 26081833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipas MVA plus (MVA), n = 122
Number of subjects: 240
Study 26081833 — intervention group
Group type: COMPARATOR
Intervention: Wallach Endocell (Endocell), n = 118
Number of subjects: 240
Study 23370795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/70 kg i.v. buprenorphine in humans
Number of subjects: 0
Study 23370795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg i.v. buprenorphine in rats
Number of subjects: 0
Study 23370795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg i.v. buprenorphine in rats
Number of subjects: 0
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style (anger-in)
Number of subjects: 35
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style (alexithymia)
Number of subjects: 35
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style (emotional expression)
Number of subjects: 35
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness knowledge
Number of subjects: 35
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles (anger-in, alexithymia, emotional expression)
Number of subjects: 35
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Denial-based coping styles
Number of subjects: 35
Study 20561886 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding communication of emotions
Number of subjects: 35
Study 19167910 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic management and extubation in the operating room (early group [EG])
Number of subjects: 100
Study 19167910 — intervention group
Group type: COMPARATOR
Intervention: Elective prolonged mechanical ventilation (control group [CG])
Number of subjects: 100
Study 17204725 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 83
Study 17204725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 83
Study 17204725 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 83
Study 14757950 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-propagation network with variable degree variable step size LMS algorithm
Number of subjects: 0
Study 10716458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochalasin B
Number of subjects: 43
Study 10716458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8957980 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 1000 ml (Group C)
Number of subjects: 34
Study 8957980 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 500 ml (Group B)
Number of subjects: 34
Study 8957980 — intervention group
Group type: COMPARATOR
Intervention: No fluid load (Group A)
Number of subjects: 34
Study 1525787 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg once daily
Number of subjects: 56
Study 1525787 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 56
Study 2859042 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 30
Study 2859042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 30
Study 2859042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31172873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 7.5 mg of sodium metaphosphate (SMP)
Number of subjects: 30
Study 31172873 — intervention group
Group type: COMPARATOR
Intervention: Control gum without sodium metaphosphate
Number of subjects: 30
Study 28371155 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021 20 mg
Number of subjects: 174
Study 26659938 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Volbella with Lidocaine
Number of subjects: 280
Study 26659938 — intervention group
Group type: COMPARATOR
Intervention: Restylane‐L
Number of subjects: 280
Study 22311679 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient chemotherapy with S-1 + cisplatin (S-1: 80-120 mg days 1-21; cisplatin: 60 mg/m2 day 8, every 4-5 weeks)
Number of subjects: 36
Study 22311679 — intervention group
Group type: COMPARATOR
Intervention: Inpatient chemotherapy with intravenous hydration (control group)
Number of subjects: 36
Study 21658668 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotyping using Hybrid Capture II
Number of subjects: 1595
Study 21658668 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for other high-risk HPV types
Number of subjects: 1595
Study 18473693 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM) with DIABTel telemedicine system
Number of subjects: 10
Study 18473693 — intervention group
Group type: COMPARATOR
Intervention: Control phase (blind 3-day CGM)
Number of subjects: 10
Study 17174228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 949
Study 17174228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 12690945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic strength
Number of subjects: 0
Study 12690945 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping and intrusive thinking
Number of subjects: 0
Study 12690945 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive coping
Number of subjects: 0
Study 10496451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 0
Study 10496451 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 0
Study 8947984 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive formulary (dosage strengths of 25, 50, 100, 125, and 150 micrograms)
Number of subjects: 241
Study 8947984 — intervention group
Group type: COMPARATOR
Intervention: Nonrestrictive formulary (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms)
Number of subjects: 241
Study 1680413 — intervention group
Group type: EXPERIMENTAL
Intervention: PDF with 3.86% glucose (D386)
Number of subjects: 8
Study 1680413 — intervention group
Group type: COMPARATOR
Intervention: PDF with 1.36% glucose (D136)
Number of subjects: 8
Study 7104460 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 40 mg oral propranolol hydrochloride tablets
Number of subjects: 18
Study 7104460 — intervention group
Group type: COMPARATOR
Intervention: Innovator's product (reference tablet)
Number of subjects: 18
Study 30916379 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every week (ADAew)
Number of subjects: 0
Study 30916379 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab every other week (ADAew/eow)
Number of subjects: 0
Study 30916379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ADAew/pbo)
Number of subjects: 0
Study 29463950 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted functional cognitive training (RehaCom) for 10 weeks
Number of subjects: 58
Study 29463950 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 58
Study 29463950 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted functional cognitive training (RehaCom)
Number of subjects: 58